Tariffs could raise pricesNEW YORK CITY, NY / ACCESSWIRE / November 26, 2024 / The RENN Fund, Inc. (NYSE American:RCG) (the "Fund") announced today a record date for the Fund's year-end distribution. The record date will be December 16, 2024 and Pay-Date of December 27, 2024. The Fund will make an announcement on or about December 23, 2024 with the distribution rate per share. As the per share rate will not be available prior to the record date, the Fund will trade with due bills beginning December 16, 2024, and up through and including the last business day prior to the New York Stock Exchange established Ex-Date. The New York Stock Exchange will set the Ex-Date once the per share rate has been announced. Disclosures: Fund shares are subject to investment risk, including possible loss of principal invested. No fund is a complete investment program and you may lose money investing in the Fund. An investment in the Fund may not be appropriate for all investors. Additional information about the Fund, including performance and portfolio characteristics, is available at https://horizonkinetics.com/investment-strategies/renn-fund-inc-nyse-rcg/ . About Horizon Kinetics LLC Horizon Kinetics Holding Corporation (OTC: HKHC), through its subsidiary investment manager, Horizon Kinetics Asset Management LLC ("Horizon"), is an investment advisory firm and the Investment Advisor to the Fund. Horizon provides independent proprietary research and investment advisory services for long-only and alternative value-based investing strategies, including the full suite of Kinetics Mutual Funds, Inc. The firm has offices in New York City, White Plains, New York and Summit, New Jersey. For more information, please visit Horizon's websites below: http://www.horizonkinetics.com http://www.kineticsfunds.com . Contact: Jay Kesslen Email: jkesslen@horizonkinetics.com Phone: (646) 495-7333 SOURCE: RENN FUND INC View the original on accesswire.comNigeria’s oil and gas industry witnessed a flurry of business deals such as partnerships, acquisitions, and divestments in 2024. In the upstream sector, the year saw international oil giants like Shell and TotalEnergies relinquish their assets to local players like Seplat Energy and Oando PLC. We also saw ambitious acquisitions and partnership deals involving IOCs and indigenous oil companies. Related Stories TotalEnergies extends Deepsea Mira contract in West Africa for 3 months NNPCL slashes petrol price to N899 in Lagos, N970 in other states – PETROAN While divestments and exits were witnessed mostly in onshore operations, more investments by IOCs were observed in the offshore segment. Experts suggest that the IOCs do not want to deal with local issues such as pipeline vandalism and environmental pollution, while local companies have been hailed for their investment in this area despite the risks. The year also featured significant financial investment decisions and partnerships that would shape the future of Nigeria’s energy industry. Here are some of the major deals in Nigeria’s oil and gas industry in 2024. The Norwegian energy firm, Equinor ASA finalised the sale of its Nigerian assets, a 53.85% ownership in oil and gas lease OML 128, including a 20.21% stake in the Agbami field, to Chappal Energies for up to $1.2 billion. The sale signifies the exit of Equinor Nigeria Energy Company (ENEC) from Nigeria as the parent company said it planned to “deepen further in countries where Equinor can add the most value and build a more focused and robust international portfolio.” The deal, executed through Project Odinmim a special-purpose vehicle owned by Chappal Energies—was finalized this month, after several months of delay by Nigerian regulators. Seplat Energy Plc, listed on both the Nigerian Exchange Limited and the London Stock Exchange, also completed the acquisition of Mobil Producing Nigeria Unlimited MPNU from ExxonMobil Corporation. The acquisition of the onshore asset is expected to double Seplat’s production capacity to approximately 120,000 barrels of oil equivalent per day. The deal valued at $1.2 billion was initiated in February 2022 but delayed by regulatory review until December 2024. In a deal expected to be finalised in the next couple of weeks, TotalEnergies has decided to divest from Nigeria’s onshore operations in favour of a more secure offshore environment by selling its 10% stake in the Shell Petroleum Development Company to an Indigenous company, Chappal Energies. SPDC JV is an onshore subsidiary of oil giant, Shell which has been sold to a consortium of local companies. TotalEnergies Nigeria planned to transfer its 10% interest and all associated rights and obligations in 15 SPDC JV licenses to Chappal Energies. In 2023, production from these licenses accounted for roughly 14,000 barrels of oil equivalent per day for TotalEnergies. Additionally, TotalEnergies EP Nigeria will sell its 10% interest in three other SPDC JV licenses (OML 23, OML 28, and OML 77), which focus on gas production, to Chappal Energies. However, TotalEnergies will retain full economic rights in these gas-producing licenses, which currently provide 40% of the gas supply to Nigeria LNG. This year, Oando Plc completed the acquisition of the Nigerian Agip Oil Company (NAOC) from Italian energy giant Eni in a deal worth $783 million. The acquisition was part of another divestment in the oil and gas industry as Eni quits onshore operations in Nigeria for offshore operations. Speaking on NAOC’s acquisition, the Group Chief Executive of Oando PLC, Wale Tinubu, said : “Today’s announcement is the culmination of ten years of hard work, resilience, and an unwavering belief that we would realise our ambition. It is a win, not just for Oando, but for every indigenous energy player as we take our destiny in our hands. “This is a new dawn for the Nigerian energy sector, and we are confident that indigenous companies will play a pivotal role in this next phase of the nation’s upstream evolution. With our assumption of the role of operator, our immediate focus is on optimizing the assets’ immense potential in contributing to our strategic objectives, whilst complementing the nation’s plan to boost production outputs.” Nairametrics recently reported the final investment decision (FID) of Shell Nigeria Exploration and Production Company Limited (SNEPCo) on the Bonga North deep-water project, located off Nigeria’s coast. The $5 billion offshore investment, in which Shell has a 55% stake, is expected to yield approximately 350 million barrels of crude oil. The Bonga North project includes the drilling and completion of 16 wells, modifications to the existing FPSO, and the installation of new subsea infrastructure. This development is expected to maintain oil and gas production at the Bonga facility. Speaking on the investment decision, Shell’s Integrated Gas and Upstream Director, Zoë Yujnovich, said: “This is another significant investment, which will help us to maintain stable liquids production from our advantaged Upstream portfolio.” Two Nigerian companies partner with Saipem to secure a contract on the Bongo North project Weeks after Shell’s FID on the Bongo North project, an Italian multinational oilfield services company in partnership with two Nigerian companies, KOA Oil & Gas and AVEON Offshore, secured a contract valued at approximately $1 billion from SNEPco to work on the oilfield. According to Saipem, the contract covers the Engineering, Procurement, Construction, and Installation (EPCI) of risers, flowlines, subsea umbilicals, and associated subsea structures. The Nigerian National Petroleum Company Limited (NNPCL) and Total Energies also announced a Final Investment Decision (FID) on the Ubeta oilfield (OML 58), in a partnership deal valued at $550 million. Nairametrics reported that this FID involves a commitment of $550 million to extract 900 billion cubic feet of non-associated natural gas from the oil field, situated approximately 85 kilometres from Port Harcourt in Nigeria’s Niger Delta Region. These partnerships, divestments, and investments shaped the oil and gas landscape in the year 2024 and it is expected that the gains and developments therefrom will impact the industry in the coming year President Bola Tinubu has pledged to boost Nigeria’s energy security by improving production and ensuring a conducive climate for private players to thrive.
The must-have toys every Glasgow kid wanted for Christmas in the 1990sNet power CFO Akash Patel sells $1.9 million in stockRegenerative Medicine Market to Skyrocket to USD 73,084.2 Million by 2033 at a 18.5% of CAGR 12-23-2024 06:40 PM CET | Health & Medicine Press release from: Future Market Insights Regenerative Medicine Market The global regenerative medicine market is set to witness explosive growth, with its valuation expected to surge from US$ 13,385.6 million in 2023 to an impressive US$ 73,084.2 million by 2033, according to the latest industry analysis. This reflects a robust compound annual growth rate (CAGR) of 18.5% over the forecast period. The rise in precision medicine, increased investment in regenerative medicine research, and advances in cell manufacturing and bioprocessing are the key factors driving market growth. Regenerative medicine, which focuses on restoring the function of damaged tissues and organs, is gaining momentum due to advancements in cancer biologics and 3D disease modeling technologies. The ability to simulate human disease conditions in a 3D environment allows for more precise testing of regenerative therapies, accelerating their path to clinical use. This technological shift is expected to drive the adoption of regenerative medicine in clinical settings. Request a Sample of this Report Now: https://www.futuremarketinsights.com/reports/sample/rep-gb-1326 Investments in stem cell banking, cell manufacturing, and bioprocessing facilities are further supporting the commercialization and accessibility of regenerative therapies. These investments are enabling the large-scale production of stem cells and biologics, reducing production costs and facilitating wider access to advanced therapies. Precision medicine, especially in the area of cancer treatment, is also expected to drive demand for personalized regenerative medicine solutions. With breakthroughs in bioprocessing, 3D disease modeling, and stem cell research, the regenerative medicine industry is on track for unprecedented growth. The increased commercialization of regenerative therapies, combined with growing interest from investors and healthcare providers, is expected to create lucrative opportunities for pharmaceutical companies, research institutions, and biotech firms. Key Takeaways: The global regenerative medicine market is projected to grow from US$ 13,385.6 million in 2023 to US$ 73,084.2 million by 2033, at an impressive CAGR of 18.5%. Growth is driven by advances in cancer biologics, 3D disease modeling, and the rise of precision medicine. Increased investments in stem cell banking, cell manufacturing, and bioprocessing are supporting the commercialization and large-scale production of regenerative therapies. Emerging manufacturing technologies like 3D human disease models are facilitating faster testing and validation of regenerative therapies. The growing demand for personalized, precision-based treatments is expected to fuel market expansion, creating lucrative opportunities for biotech firms, healthcare providers, and pharmaceutical companies. Key Trends in the Regenerative Medicine Industry Increased Development of Regenerative Products: There is a growing focus on developing regenerative medicine products, supported by significant investments in research and development. Advancements in Precision Medicine: As cancer biologics advance, the field of precision medicine is expected to expand, allowing for more tailored treatments for patients. Innovations in Manufacturing Technologies: The use of advanced manufacturing technologies, such as 3D models of human diseases, is facilitating the testing of regenerative medicine approaches in clinical settings. Investment in Stem Cell Banking and Bioprocessing: Growing investments in stem cell banking, cell manufacturing, and bioprocessing facilities are enhancing the commercialization and accessibility of regenerative therapies. Changing Societal Attitudes: There is a notable shift in societal attitudes towards pet animals and animal farming, which is driving demand for regenerative solutions in veterinary medicine as well. Demand for Fast and Reliable Diagnostics: The increasing need for quick and effective diagnostic techniques in regenerative medicine is creating opportunities for innovation. Competitive Landscape With several competitors in regenerative medicine, the overall industry is fragmented. To meet consumer demand and expand their customer base, these companies are implementing methods such as divestiture, partnerships and collaborations, and new therapy launches. Some of the developments by players in the regenerative medicine industry are given below In January 2022 - Stryker's president joins the board of the regenerative medicine company Collagen Matrix, which will accelerate the growth strategy and further their vision of improving patient lives through innovative regenerative devices In January 2021, Integra LifeSciences Holdings Corporation divestiture of its Extremity Orthopaedics business to Smith & Nephew, which will contribute to technologies in orthopedics and regenerative medicines. Key Companies Profiled 3M Allergan plc Amgen, Inc. Aspect Biosystems bluebird bio Kite Pharma Integra LifeSciences Holdings Corporation MEDIPOST Co., Ltd. Anterogen Co., Ltd. MiMedx Group Misonix, Organogenesis Inc. Orthocell Limited Corestem, Inc. Spark Therapeutics APAC Biotech Shenzhen Sibiono GeneTech Co., Ltd. Smith & Nephew plc Stryker Corporation Key Industry Segments Covered In Regenerative Medicine Industry Research By Therapy type: Cell Therapy Autologous Cell Therapy Allogenic Cell Therapy Stem Cell Therapy Allogeneic Stem Cell Therapy Autologous Stem Cell Therapy Tissue-engineering Gene Therapy By Application: Wound Care Musculoskeletal Oncology Dental DMD (Duchenne Muscular Dystrophy) Hepatological Diseases Inflammatory & Autoimmune Diseases Other Therapeutic Applications By Region: North America Latin America Western Europe Eastern Europe South Asia and Pacific East Asia Middle East and Africa Explore FMI's Related Ongoing Coverage on Healthcare Market Insights Domain: Autism Spectrum Disorder Management Market - https://www.futuremarketinsights.com/reports/autism-spectrum-disorder-management-market Atrial Appendage Occluder Market - https://www.futuremarketinsights.com/reports/atrial-appendage-occluder-market Cell Culture Incubator Market - https://www.futuremarketinsights.com/reports/cell-culture-incubator-market About Future Market Insights (FMI) Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries. Contact Us: Future Market Insights Inc. Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, USA T: +1-347-918-3531 For Sales Enquiries: sales@futuremarketinsights.com Website: https://www.futuremarketinsights.com LinkedIn| Twitter| Blogs | YouTube This release was published on openPR.
Phillies gamble on 1-year contract for 2-time All-Star closer Jordan RomanoNone
About 43,000 Ukrainian soldiers have died defending their homeland from invading Russian armies in the three years since dictator Vladimir Putin launched the war, Ukrainian President Volodymyr Zelensky has said in a rare casualty update. That tally — which is about 15,000 less than what the US lost during eight years of fighting in Vietnam — doesn’t count the wounded, which Zelensky said has eclipsed about 370,000, according to The Independent. Some of those soldiers were wounded more than once, and some of the injuries were minor. But the casualty list is still shocking in an era when full-scale ground wars are relatively rare. “Our people are defending their homes at the cost of their lives, and every life of our soldiers and our civilians is precious to us,” Zelensky said in the statement. Until now, neither Russia nor Ukraine have shared total military losses, with the outlet saying they are treated as state secrets. But Zelensky added that Ukrainian troops have killed about 198,000 Russian soldiers and wounded more than a half-million. Russian losses have surged in the last few months, he added — even as the invaders slowly gain ground in their advance across eastern Ukraine. “Since September of this year, Russia has been losing people on the battlefield in a ratio of 5 and even 6 to 1 for us,” the president wrote on his Telegram channel. “This is how they want to seize more land before the world’s pressure on them can become unbearable.” President-elect Donald Trump has called on Putin to green-light an “immediate ceasefire” — but it’s unclear if his entreaties will work. “Zelensky and Ukraine would like to make a deal and stop the madness,” Trump wrote on social media Sunday.